You are here

SLAS DISCOVERY: Advancing Life Sciences R&D

SLAS DISCOVERY: Advancing Life Sciences R&D

Advancing Life Sciences R&D

Editor-in-Chief
Robert M. Campbell, PhD Eli Lilly & Company, Indianapolis, IN, USA


eISSN: 24725560 | ISSN: 24725552 | Current volume: 23 | Current issue: 9 Frequency: 10 Times/Year

Advancing Life Sciences R&D: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.

SLAS Discovery is a peer-reviewed journal focusing on drug discovery sciences with a strong record of scientific rigor and impact. SLAS Discovery is an official journal of SLAS.

Come Transform Research with SLAS: SLAS Discovery and SLAS Technology readers, authors, editors and reviewers are academic, commercial and government researchers, scientists and engineers who conduct research, and develop and implement new technologies. Together, these journals address the full spectrum of issues that are mission-critical to this important audience, enabling research teams to gain scientific insights; increase productivity; elevate data quality; reduce process cycle times; and enable research and development that otherwise would be impossible.

Click here for more information about SLAS Discovery’s editorial aims and scope.

SLAS Discovery is a member of the Committee on Publication Ethics (COPE) and was published previously (1996-2016) as the Journal of Biomolecular Screening (JBS).

Advancing Life Sciences R&D: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.

SLAS Discovery is a peer-reviewed journal that publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success.

SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies.

SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology.

SLAS Discovery is a member of the Committee on Publication Ethics (COPE) and was published previously (1996-2016) as the Journal of Biomolecular Screening (JBS).

Editor-in-Chief
Robert M. Campbell, PhD Eli Lilly & Company, Indianapolis, IN, USA
Associate Editors
Marc Bickle, PhD Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
Christian Parker, PhD Novartis Institutes for Biomedical Research, Basel, Switzerland
Kirti Sharma, PhD Kymera Therapeutics, Cambridge, MA, USA
Reviews Editor
Peter Simpson, PhD Medicines Discovery Catapult, Cheshire, UK
Scientific Advisors
Ricardo Macarrón, PhD GlaxoSmithKline R&D, Collegeville, PA, USA
Lorenz M. Mayr, PhD GE Healthcare Life Sciences, Amersham, UK
D. Lansing Taylor, PhD University of Pittsburgh, Pittsburgh, PA, USA
Editorial Board
James Beasley, PhD Venenum Biodesign, Hamilton, NJ, USA
Christine Brideau, BS WuXi AppTec, Holmdel, NJ, USA
Mei Ding, PhD AstraZeneca, Gothenburg, Sweden
Hakim Djaballah, PhD Keren Therapeutics, New York, NY, USA
Marc Ferrer, PhD NIH Chemical Genomics Center, Rockville, MD, USA
Robert A. Goodnow, Jr, PhD Pharmaron, Boston, MA, USA
Charles Hart, PhD Threshold Pharmaceuticals, South San Francisco, CA, USA
Rob Howes, PhD AstraZeneca, Gothenburg, Sweden
David J. Kahler, PhD, PMP NYU High-Throughput Biology Laboratory, New York, NY, USA
Jeroen Kool, PhD Vrije Universiteit Amsterdam, Netherlands
Martin Main, PhD Medicines Discovery Catapult, Alderley Park, Cheshire, UK
Jose Julio Martin-Plaza, PhD GlaxoSmithKline, Tres Cantos, Spain
Larry Mattheakis, PhD Protagonist Therapeutics, Milpitas, CA, USA
James McGee, PhD Eli Lilly & Company, Indianapolis, IN, USA
Joseph McGivern, PhD Amgen Inc., Thousand Oaks, CA, USA
Robert Nadon, PhD Department of Human Genetics, McGill University, McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada
Katja Remlinger, PhD GlaxoSmithKline, Raleigh-Durham, NC, USA
Mariafrancesca Scalise, PhD University of Calabria, Cosenza, Italy
Timothy Spicer, MSc The Scripps Research Institute, Jupiter, FL, USA
Masoud Vedadi, PhD University of Toronto, Canada
Francisca Vicente, PhD Fundación MEDINA, Granada, SPAIN
Andreas Vogt, PhD University of Pittsburgh Drug Discovery Institute, Pittsburgh, PA, USA
Mark Wade, PhD Astex Pharmaceuticals, Cambridge, UK
Director of Publishing
Nan Hallock Society for Laboratory Automation and Screening - Manitowoc, WI, USA
  • BIOSIS database
  • Biomolecular Interaction Network Database (BIND)
  • Biotechnology Citation Index®
  • Chemical Abstracts Service (CAS)
  • Clarivate Analytics: BIOSIS Previews
  • Clarivate Analytics: Current Contents - Life Sciences
  • EMBASE/Excerpta Medica
  • EMBiology
  • Elsevier BV: BIOBASE
  • Index Medicus
  • InfoTrac (full text)
  • Prous Science Integrity®
  • PubMed: MEDLINE
  • Science Citation Index Expanded (Web of Science)
  • Scopus
  • Individual Subscription, Print Only


    Institutional Subscription, E-access


    Institutional Backfile Purchase, E-access (Content through 1998)


    Institutional Subscription, Print Only


    Institutional Subscription & Backfile Lease, E-access Plus Backfile (All Online Content)


    Institutional Subscription, Combined (Print & E-access)


    Institutional Subscription & Backfile Lease, Combined Plus Backfile (Current Volume Print & All Online Content)


    Individual, Single Print Issue


    Institutional, Single Print Issue